It is noteworthy that c-Myc, a master transcription factor recently found to be the major target of BRD4 in cancer cells (Delmore et al., 2011), was not altered in rat SMCs following JQ1(+) treatment (Guo et al., unpublished data), highlighting a cell type specificity of BET regulations. Here, MYC is linked to cancer.